{
  "docId": "019de076-9bf1-74fc-a35c-18d7d86ef549",
  "docSlug": "50ca0b93fcc5c9425705539b9e6fcccb",
  "documentTitle": "Erasca | Investor Presentation Deck | 41 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 41,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "Includes waterfall plot and swimmer plot for clinical trial results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-9bf1-74fc-a35c-18d7d86ef549/26",
  "deckHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549",
  "deckJsonHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549.json",
  "deckAnchorHref": "/decks/019de076-9bf1-74fc-a35c-18d7d86ef549#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.52,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Efficacy-Evaluable Patients (Time on Treatment)",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85693dcb-ca8b-497d-9713-a16535283ad5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Best Change in Sum of Measurable Target Lesion Diameters From Baseline (%)",
      "attrs": null,
      "subkind": "waterfall",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c166bf8-b9d1-4b5b-a14d-7da9e4a35d93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.55,
        "y": 0.63
      },
      "kind": "disclaimer",
      "text": "Data cutoff as of 21MAY2023. Response on the bar represents the best overall response based on investigator assessments.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c353448b-66ff-4581-af1b-8763b4810c1a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.5,
        "x": 0.05,
        "y": 0.63
      },
      "kind": "list",
      "text": "In EC-naïve BRAFm CRC patients at the highest dose tested (100 mg BID-QW): 50% (3/6) response rate; 67% (4/6) disease control rate; Both confirmed responders were still on treatment >40 weeks. In EC-naïve BRAFm CRC patients across all dose levels: 38% (3/8) response rate; 63% (5/8) disease control rate",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e3b911a-2198-41ec-ab2c-8d2799817b41",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.02,
        "y": 0.02
      },
      "kind": "title",
      "text": "Meaningful activity in EC-naïve BRAFm CRC supports initial focus on and dose expansion of this patient segment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7f36824-573a-4c9d-b823-e5dd51cb9222",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Waterfall chart",
      "slug": "waterfall-chart",
      "agent": null,
      "layer": "slide",
      "matchId": "398ed3bc-6cb2-4cbe-98d2-f627d098e0f9",
      "evidence": "chart/waterfall: Best Change in Sum of Measurable Target Lesion Diameters From Baseline (%)",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 30,
      "from": 21,
      "beatId": "3afa2661-92f3-43bb-b45e-80e199ce2c84",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": null,
      "evidence": "Describing the potential benefits of Erasca's pipeline",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}